 |
|
|
| |
Preliminary Results From a Phase 2 Study Evaluating VIR-2218 Alone and in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis B Infection
|
| |
| |
AASLD 2021 Nov 12-15
Man-Fung Yuen1, Young-Suk Lim2, Daniel Cloutier3, Vaidehi Thanawala3, Ling Shen3, Andre Arizpe3, Chin Tay3, Sneha Gupta3, Andrea L Cathcart3, Carey Hwang3, Phillip S. Pang3, and Edward Gane4
1The University of Hong Kong, Hong Kong, China; 2University of Ulsan College of Medicine, Seoul, Korea; 3Vir Biotechnology Inc., San Francisco, California, USA; 4University of Auckland, Auckland, New Zealand
|
| |
|
|
|
|
|
